接受CAR-T细胞治疗患者的COVID-19结局随时间改善:欧洲COVID-19多中心研究的更新——代表欧洲血液与骨髓移植学会(EBMT)感染性疾病工作组(IDWP)和欧洲血液学协会(EHA)淋巴瘤组
该多中心研究纳入180例接受CAR-T细胞治疗并感染COVID-19的患者,比较2020、2021和2022年(奥密克戎时期)的结局。COVID-19相关死亡率随时间 successively 下降(2020年43.6%,2021年22.9%,2022年7.5%),感染年份是生存的最强预测因素(p=0.0001)。2022年与2020-2021年相比,下呼吸道症状、需氧支持和ICU入住率均显著降低。
要点
- COVID-19相关死亡率随时间下降:2020年43.6%,2021年22.9%,2022年7.5%。
- 多因素分析中感染年份是生存的最强预测因素(p=0.0001)。
- 2022年较2020-2021年下呼吸道症状、需氧支持和ICU入住率显著降低。
核心结论
- 尽管COVID-19相关死亡率随时间下降,CAR-T细胞接受者并发症风险仍高于普通人群,持续推荐对接受B细胞靶向CAR-T细胞治疗的患者进行 vigilant COVID-19监测,确保最佳感染预防和必要时先进治疗。
研究设计与样本
- 多中心研究,使用EBMT开发的MED-A和COVID-19报告表收集数据,共纳入180例患者,2020年诊断39例,2021年35例,2022年106例,中位年龄58.9岁(最小-最大:5.2-78.4)。
主要发现
- COVID-19相关死亡率随时间 successively 下降:2020年43.6%,2021年22.9%,2022年7.5%。
- 多因素分析中感染年份是生存的最强预测因素(p=0.0001)。
- 2022年与2020-2021年比较,下呼吸道症状更少(21.7% vs 37.8%,p=0.01),需氧支持更少(25.5% vs 43.2%,p=0.01),ICU入住更少(5.7% vs 33.8%,p=0.0001)。
临床怎么用
- 作者建议持续推荐对接受B细胞靶向CAR-T细胞治疗的患者进行 vigilant COVID-19监测,确保最佳感染预防和必要时先进治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COVID-19 has been associated with high mortality in patients treated with Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. Here, we investigated whether the outcome has improved over time with the primary objective of assessing COVID-19-attributable mortality in the Omicron period of 2022 compared to previous years. Data for this multicenter study were collected using the MED-A and COVID-19 report forms developed by the EBMT. One-hundred-eighty patients were included in the analysis, 39 diagnosed in 2020, 35 in 2021 and 106 in 2022. The median age was 58.9 years (min-max: 5.2-78.4). There was a successive decrease in COVID-19-related mortality over time (2020: 43.6%, 2021: 22.9%, 2022: 7.5%) and in multivariate analysis year of infection was the strongest predictor of survival (p = 0.0001). Comparing 2022 with 2020-2021, significantly fewer patients had lower respiratory symptoms (21.7% vs 37.8%, p = 0.01), needed oxygen support (25.5% vs 43.2%, p = 0.01), or were admitted to ICU (5.7% vs 33.8%, p = 0.0001). Although COVID-19-related mortality has decreased over time, CAR T-cell recipients remain at higher risk for complications than the general population. Consequently, vigilant monitoring for COVID-19 in patients undergoing B-cell-targeting CAR T-cell treatment is continuously recommended ensuring optimal prevention of infection and advanced state-of-the art treatment when needed.
引用
- Spanjaart AM, Ljungman P, Tridello G, et al. Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group. Leukemia. 2024. PMID: 39043963. doi:10.1038/s41375-024-02336-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。